| Ytd | 15.18% | |
| 1y | 110.85% |
| Open | 23.77 | Prev Close | 23.63 | Low | 23.27 | High | 25.27 | Mkt Cap | 969.43M |
| Vol | 696.84K | Avg Vol | 378.98K | EPS | -1.76 | P/E | N/A | Forward P/E | -24.29 |
| Beta | 0.94 | Short Ratio | 2.68 | Inst. Own | 39.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 23.40 | 200-d Avg | 20.45 | 1yr Est | 33.25 |
CBLL News
TD Cowen analyst Joshua Jennings maintains CeriBell (NASDAQ:CBLL) with a Buy and raises the price
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
BTIG analyst Marie Thibault maintains CeriBell (NASDAQ:CBLL) with a Buy and raises the price targ
Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and raises
CeriBell (NASDAQ:CBLL) raises FY2026 sales outlook from $112.000 million-$116.000 million to $114.00
CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology com
CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology com
CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transform
Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and lowers
CeriBell (NASDAQ:CBLL) raises FY2026 sales outlook from $111.000 million-$115.000 million to $112.00
CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.52) per share which missed the analyst conse
CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.36) per share which beat the analyst consens
Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and raises
CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transfor
JP Morgan analyst Robbie Marcus maintains CeriBell (NASDAQ:CBLL) with a Overweight and lowers the
TD Cowen analyst Joshua Jennings maintains CeriBell (NASDAQ:CBLL) with a Buy and lowers the price
2025 Financial OutlookCeribell is raising its revenue guidance for the full year 2025 to a range of
CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.37) per share which beat the analyst consens
Raymond James analyst Jayson Bedford initiates coverage on CeriBell (NASDAQ:CBLL) with a Strong B
CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.38) per share which beat the analyst consens
CeriBell (NASDAQ:CBLL) raises FY2025 sales outlook from $83.000 million-$87.000 million to $85.000 m
CeriBell (NASDAQ:CBLL) raises FY2025 sales outlook from $81.00 million-$85.00 million to $83.00 mill
Ceribell is one of only 51 companies in the U.S. to achieve FedRAMP High authorizationCeribell's
The U.S. government has recently announced a broad range of tariffs ("incremental tariffs")
Ladenburg Thalmann analyst Jeff Cohen initiates coverage on CeriBell (NASDAQ:CBLL) with a Buy rat
Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and mainta
CeriBell (NASDAQ:CBLL) reported quarterly losses of $(0.40) per share which missed the analyst conse
Shares of MicroStrategy Incorporated (NASDAQ:MSTR) rose sharply in today's pre-market trading.
TD Cowen analyst Joshua Jennings maintains CeriBell (NASDAQ:CBLL) with a Buy and raises the price
Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and raises
Canaccord Genuity analyst William Plovanic maintains CeriBell (NASDAQ:CBLL) with a Buy and raises
CeriBell (NASDAQ:CBLL) reported quarterly losses of $(1.85) per share. This is a 40.15 percent decre
—Ceribell System stands to reduce costly ICU admissions and intra-facility patient transfers——Milita
JP Morgan analyst Robbie Marcus initiates coverage on CeriBell (NASDAQ:CBLL) with a Overweight ra
William Blair analyst Margaret Kaczor initiates coverage on CeriBell (NASDAQ:CBLL) with a Outperf